Switching from intravenous to subcutaneous vedolizumab maintenance treatment; feasibility, safety and clinical outcome

被引：0
|
作者：
Wiken, T. [1 ,2 ]
Hoivik, M. L. [1 ,2 ]
Buer, L. [1 ]
Bolstad, N. [3 ]
Moum, B. A. [1 ,2 ]
Medhus, A. W. [1 ]
机构：
[1] Oslo Univ Hosp, Dept Gastroenterol, Oslo, Norway
[2] Univ Oslo, Inst Clin Med, Oslo, Norway
[3] Oslo Univ Hosp, Dept Med Biochem, Oslo, Norway
来源：
JOURNAL OF CROHNS & COLITIS | 2022年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P376
引用
收藏
页码：I378 / I379
页数：2
相关论文
共 50 条
  • [41] Switching from intravenous to subcutaneous Infliximab in patients with immune mediated diseases in clinical remission
    Viazis, N.
    Karamanakos, A.
    Mousourakis, K.
    Christidou, A.
    Fousekis, F.
    Mpakogiannis, K.
    Koukoudis, A.
    Katsanos, K.
    Christodoulou, D.
    Cheila, M.
    Tzouvala, M.
    Zacharopoulou, E.
    Palatianou, M.
    Giouleme, O.
    Katsoula, A.
    Liatsos, C.
    Kyriakos, N.
    Zampeli, E.
    Papathanasiou, E.
    Theodoropoulou, A.
    Karmiris, K.
    Psaroudakis, I
    Tribonias, G.
    Gazi, S.
    Mole, E.
    Dimitroulas, T.
    Koutsianas, C.
    Vasilopoulos, D.
    Fragoulis, G.
    Michalakeas, N.
    Papagoras, C.
    Panagakis, P.
    Papoutsaki, M.
    Chasapi, V
    Stratigos, A.
    Katsikas, G.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1773 - i1773
  • [42] Transitioning from Intravenous to Subcutaneous Vedolizumab in Patients with Inflammatory Bowel Disease [TRAVELESS]
    Ventress, Esther
    Young, David
    Rahmany, Sohail
    Harris, Clare
    Bettey, Marion
    Smith, Trevor
    Moyses, Helen
    Lech, Magdalena
    Gwiggner, Markus
    Felwick, Richard
    Cummings, J. R. Fraser
    JOURNAL OF CROHNS & COLITIS, 2022, 16 (06): : 911 - 921
  • [43] Evaluation of the transition from intravenous to subcutaneous vedolizumab in patients with inflammatory bowel disease
    Costa, Carmen Amor
    Ferrer, Cristina Suarez
    Ramirez, Laura Garcia
    Martin-Arranz, Eduardo
    Cordon, Joaquin Poza
    Garcia, Jose Luis Rueda
    Azofra, Maria Sanchez
    Diaz, Irene Gonzalez
    Roig, Clara Amiama
    Martin-Arranz, Maria Dolores
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2025, 48 (03):
  • [44] TRANSITIONING FROM INTRAVENOUS TO SUBCUTANEOUS VEDOLIZUMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (TRAVELESS)
    Ventress, Esther
    Rahmany, Sohail
    Young, David
    Bettey, Marion
    Harris, Clare
    Moyses, Helen
    Smith, Trevor
    Felwick, Richard
    Gwiggner, Markus
    Cummings, Fraser
    GUT, 2021, 70 : A83 - A84
  • [45] Patient benefits of switching from intravenous to subcutaneous infliximab
    Rahmany, Sohail
    Young, David
    Latter, Sue
    Cummings, Fraser
    GUT, 2023, 72 (SUPPL_2) : A105 - A105
  • [46] Remission Is Maintained after Switch from Dose-Optimised Intravenous Treatment to Subcutaneous Treatment with Vedolizumab in Inflammatory Bowel Disease
    Pintar, Spela
    Hanzel, Jurij
    Drobne, David
    Kozelj, Matic
    Kurent, Tina
    Smrekar, Natasa
    Novak, Gregor
    MEDICINA-LITHUANIA, 2024, 60 (02):
  • [47] Long-Term Safety, Outcome, and Clinical Effects of Subcutaneous and Intravenous Treprostinil Treatment in Patients with Severe Chronic Pulmonary Arterial Hypertension
    Harutyunova, Satenik
    Benjamin, Nicola
    Eichstaedt, Christina
    Marra, Alberto M. M.
    Xanthouli, Panagiota
    Nagel, Christian
    Gruenig, Ekkehard
    Egenlauf, Benjamin
    RESPIRATION, 2023, 102 (08) : 579 - 590
  • [48] FEASIBILITY OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS IMMUNOGLOBULIN MAINTENANCE THERAPY IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY: A COMPARISON OF PATH TRIAL RESULTS WITH REAL-WORLD EXPERIENCE
    Cocito, D.
    Peci, E.
    Bril, V
    van Geloven, N.
    Hartung, H.
    Lewis, R.
    Sobue, G.
    Lawo, J.
    Mieke, O.
    Durn, B.
    Cornblath, D.
    Merkies, I
    van Schaik, I
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2019, 24 : S14 - S15
  • [49] Feasibility of Switching from Intravenous to Subcutaneous Immunoglobulin Therapy in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Comparison of PATH Trial Results with Clinical Experience
    Cocito, D.
    Peci, E.
    Romagnolo, A.
    Bril, V.
    van Geloven, N.
    Hartung, H. -P.
    Lewis, R. A.
    Sobue, G.
    Lawo, J. -P.
    Mielke, O.
    Durn, B. L.
    Cornblath, D. R.
    Merkies, I. S.
    van Schaik, I. N.
    EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 373 - 373
  • [50] Variety Beach: Real-world Treatment Patterns for Vedolizumab Intravenous and Subcutaneous Maintenance Dosing Observed Over 1 Year in Studies From Belgium, Austria and Switzerland
    Novacek, Gottfried
    Hruz, Petr
    Hoegenauer, Christoph
    Louis, Edouard
    Vavricka, Stephan R.
    Moschen, Alexander R.
    Biedermann, Luc
    Maechler, Caroline
    Stemberger, Beate
    Van Gassen, Geert
    Baert, Filip
    SWISS MEDICAL WEEKLY, 2024, 154 : 32S - 32S
12345